Prospects for combining immune checkpoint blockade with PARP inhibition

Prospects for combining immune checkpoint blockade with PARP inhibition

Abstract The immunogenicity of a cancer cell is derived from accumulated somatic mutations. However, on the contrary to increased immunogenicity, anti-cancer immune response tends to be feeble. This impaired anti-cancer immunity could be attributed to multiple factors including loss of immunodominan...

Full description

Bibliographic Details
Main Authors: Anping Li, Ming Yi, Shuang Qin, Qian Chu, Suxia Luo, Kongming Wu
Format: Article
Language:English
Published: BMC 2019-09-01
Series:Journal of Hematology & Oncology
Subjects:
PARP inhibitor
DNA damage response
PD-1
PD-L1
CTLA-4
Immunotherapy
Online Access:http://link.springer.com/article/10.1186/s13045-019-0784-8

Internet

http://link.springer.com/article/10.1186/s13045-019-0784-8

Similar Items